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Abstract: Infliximab was the first monoclonal antibody to human necrosis factor alpha 
(TNFα) developed for treating rheumatoid arthritis (RA). This chimeric antibody binds 
with high affinity to both soluble and trans-membrane TNF and is able to reduce synovial 
inflammation, bone resorption and cartilage degradation. The efficacy of infliximab has been 
observed in active RA despite treatment with multiple disease modifying anti-rheumatic drugs 
(DMARDs), and in early disease with no prior treatment by methotrexate (MTX). Infliximab 
has been shown to reduce joint inflammation and to slow radiographic progression, in both 
clinical and non-clinical responders. Recent data suggest that using infliximab early in RA 
treatment increases the percentage of clinical remission and allows infliximab discontinuation. 
The recommended dosage of 3 mg/kg could be increased up to 10 mg/kg with partial efficacy 
of the dose escalation. Antibodies to infliximab have been observed in 7% to 61% of patients 
and are associated with a low trough level of infliximab and secondary response failure. Their 
occurrence could be prevented by co-medication with MTX. The combination of DMARDs 
other than MTX with infliximab was found to be safe and efficacious. Infections, principally 
tuberculosis, are increased in treated patients, and the risk is greater at higher dose. Even if 
the treatment is generally safe and well tolerated, patients treated with infliximab should be 
closely monitored.
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Rheumatoid arthritis (RA) is a chronic disease characterized by an immune medi-
ated inflammatory synovitis leading to joint cartilage and bone destruction.1 The 
inflammatory cells of synovial RA release numerous cytokines, including tumor 
necrosis factor alpha (TNFα), interleukin 1 (IL-1) and interleukin 6 (IL-6).2 The 
key factor in inflammation and matrix destruction is TNFα, whose level has been 
found to have a strong relationship with the extent of the synovitis and with erosion 
in RA joints.3 In RA patients, TNF blockade has shown a remarkable efficacy in 
reducing joint inflammation, slowing radiographic progression of joint damage, and 
improving physical function.4 Today there are three registered TNF antagonists, 
infliximab, etanercept and adalimumab. Clinical trials are ongoing for two others, 
certolizumab and golimumab.5 Infliximab, initially called cA2, was the first TNF 
antagonist authorized for the treatment of RA, in 1998 in the US. Infliximab is a 
chimeric anti-TNF monoclonal antiboby, with murine variable regions and human 
IgG1 constant region.6 This review evaluates the therapeutic use of infliximab in Biologics: Targets & Therapy 2009:3 184
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RA, summarizing data on its mode of action, efficacy 
and safety.
What is the place of   TNF in the 
pathogenesis of RA?
In RA pathogenesis, TNF plays a central role in the 
pro-inflammatory cytokine cascade. It induces the production 
of other inflammatory cytokines, such as IL-1 and 
IL-6; recruits inflammatory cells into the joints, stimulates 
the expression of adhesion molecules in the synovial 
endothelium and the secretion of matrix metalloproteinases 
by chondrocytes and synovial fibroblasts and amplifies bone 
resorption by promoting osteoclast differentiation.3,7,8
TNFα is released from synovial macrophages as 
a soluble cytokine (sTNFα), a homotrimer of 17 KDa 
monomers, after being enzymatically cleaved from its 
cell surface-bound precursor, the transmembrane TNFα 
(tmTNFα) by TNFα−converting enzyme (TACE). Both 
sTNFα and tmTNFα are biologically active and interact 
with either of two distinct receptors, TNFR1 (p55, CD120a) 
and TNFR2 (p75, CD120b). Both sTNFα and tmTNFα 
play an important role in the pro-inflammatory functions 
of TNFα.8 Receptor-mediated effects of TNFα can lead 
alternatively to cell activation or apoptosis, depending on 
the metabolic stage of the cell. TmTNFα can also receive 
signals and act as a receptor.9 TmTNFα binding by TNFRs 
or TNFα antagonists can induce a reverse signaling and 
trigger cell activation, cytokine suppression or apoptosis, 
depending on the density of tmTNFα expression, and the 
ability of cross linkage.
TNF antagonist therapy reduces many of the hallmarks 
of chronic inflammation, such as leukocyte recruitment and 
the production of inflammatory mediators.7 Fixation of sTNF 
or tmTNF by TNF antagonists can induce two mechanisms 
of action: blockade of the TNFR-mediated mechanisms and 
induction of the tmTNF-mediated mechanisms.8 Each TNF 
antagonist is able to bind to sTNF and tmTNF. However, 
the binding affinity of the different TNF blockers for TNF 
is not the same. Infliximab binds with a high affinity to 
both the 17 kDa monomer and the 51 kDa trimer forms of 
sTNF. As a bivalent monoclonal antibody, infliximab binds 
two sTNF trimers simultaneously which allows multimeric 
complexes to form. Infliximab can also bind strongly to 
tmTNF on human cells and stimulate reverse signaling. 
Binding of tmTNF by infliximab bivalent monoclonal 
antibody can favor the cross-linkage of tmTNF and cell 
signal triggering, depending on the density of tmTNF on 
the cell surface.8
TNF blockade in RA joints regulates the action of TNF 
on three targets: synovial tissue inflammation, bone erosion 
and cartilage destruction.
The effect of anti-TNFα drugs on the regulation of 
synovial tissue inflammation and the relative roles of 
reduced cell influx, apoptosis or cytotoxicity has not yet been 
clearly elucidated.10,11 However, in RA patients, infliximab 
therapy is quickly followed by a reduction in swollen joint 
numbers in parallel with a reduction of the cellularity in the 
inflamed synovial tissue as a consequence of the action of 
TNF antagonists on cell trafficking.11 Apoptosis of synovial 
infiltrating cells has also been observed, but not in the early 
stages after infliximab infusion. Complement dependent 
cytotoxicity (CDC) or antibody-dependent cell-mediated 
cytotoxicity (ADCC) could also play a role in reducing 
synovial cellularity.8
Another action of infliximab is the regulation of immune 
responses by restoring the altered regulatory T (Treg) cell 
function in RA.12 The function of CD4 + CD25 + Treg 
is the suppression of auto-reactivity and the regulation 
of immune response. This function is reduced in patients 
with RA compared to healthy individuals.13 Several recent 
clinical studies have provided evidence that infliximab could 
restore the capacity of Treg to suppress proinflammatory 
cytokine secretion by activated T cells and monocytes in 
RA patients.14–16
The most compelling clinical manifestations of the 
efficacy of TNF antagonists in RA patients are the slowing 
and even the complete arrest of bone destruction.6 Bone 
erosion is mediated by osteoclasts, multinucleated cells 
derived from monocytes-macrophages osteoclast precursors. 
Osteoclast-mediated bone resorption is promoted by TNF, 
in synergy with RANKL (Receptor Activator of Nuclear 
factor Kappa B Ligand).17 RANKL is a growth factor for 
osteoclast lineage cells.18 The maturation of the precursors, 
and the differentiation, activation and survival of osteoclasts, 
depend greatly on RANKL. RANKL is produced mainly by 
osteoblasts in healthy individuals and also, in RA patients, 
by activated T cells and fibroblast-like synoviocytes. TNF 
promotes osteoclastogenesis by directly acting on osteoclast 
lineage cells, but also indirectly, by promoting synovial 
inflammation and RANKL production. TNF blockade has 
been shown to decrease osteoclast formation.19,20 Infliximab 
could directly inhibit osteoclast formation and activity in 
vitro.19 Furthermore, infliximab inhibits the expression of 
RANKL.8 Finally, the rapid reduction in synovial macro-
phage numbers after TNF blockade may help in reducing 
the numbers of osteoclasts.8Biologics: Targets & Therapy 2009:3 185
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Cartilage  destruction  is  mediated  by  matrix 
metalloproteinases (MMPs) and other enzymes produced 
by synovial cells and chondrocytes when stimulated by 
cytokines, such as TNF, IL-1 and IL-6. TNF plays a critical 
role in the induction of these matrix-degrading enzymes in 
RA and TNF blockade reduces MMP production.8,20
Efficacy of infliximab in RA
Data from clinical trials
Since 1992, infliximab has been used in different clinical 
trials to assess its efficacy and safety in RA patients with 
various disease durations.6,21,22 In the first infliximab studies, 
patients had active disease of long duration that had not 
adequately responded to one or more classical disease 
modifying anti-rheumatic drugs (DMARDs), more often 
methotrexate (MTX). Infliximab was administrated as 
an intravenous infusion with a dosage ranging from 1 to 
20 mg/kg, alone or in combination with MTX at a dose of 
7.5 to 20 mg/week. These first trials showed that removal 
of excess TNF using infliximab was efficacious and well 
tolerated in RA patients and the combination of infliximab 
with MTX gave a more efficacious and durable response.
The efficacy of infliximab therapy on RA clinical 
symptoms was assessed in the pivotal ATTRACT (Anti-TNF 
Trial in Rheumatoid Arthritis with Combination Therapy) 
trial.23–25 This trial enrolled a total of 428 RA patients 
with active disease despite MTX therapy. The baseline 
demographic characterization of the trial population indicated 
that patients suffered from active erosive disease despite treat-
ment with multiple DMARDs (average 3.6 including MTX) 
over a mean duration of more than 8 years. Patients were 
randomized into five parallel groups: four groups were treated 
with infliximab at 3 or 10 mg/kg every 4 or 8 weeks plus 
MTX, and the fifth group was given MTX with placebo infu-
sion every 4 weeks. The efficacy of infliximab was evaluated 
at week 30, based on the ACR20 response,23 and at week 54 
for joint damage.24 The main results indicated that patients 
receiving infliximab in combination with MTX presented 
a rapid improvement of their signs and symptoms: ACR20 
response criteria were achieved in 50% of patients receiving 
infliximab compared with 20% of patients on placebo.23 The 
radiological data showed a significantly higher rate of bone 
erosion in patients treated with placebo than those treated 
with infliximab.24 Patients included in ATTRACT continued 
to receive infliximab and MTX, or MTX alone unblinded 
during a second-year extension.25 The response rates 
observed during the ATTRACT trial were maintained over 
102 weeks. In addition, the infliximab plus MTX regimens 
resulted in a significantly greater improvement in HAQ and 
SF-36 physical component summary scores, and a lesser 
radiological progression.25
Efficacy of infliximab was also observed in RA patients 
with early disease (3 years) and no prior treatment with 
MTX, in the ASPIRE (Active controlled Study of Patients 
receiving infliximab for the treatment of Rheumatoid 
arthritis of Early onset) study.26 This was the largest trial 
with infliximab, including 1049 patients, randomized into 
three groups, MTX with placebo or MTX with infliximab 
(3 or 6 mg/kg). Patients were evaluated on the basis of 
percentage of ACR improvement (ACR-N) from baseline 
to week 54. At week 54, the median improvements in 
ACR-N were significantly higher in patients receiving 
infliximab than in placebo. In the same way, ACR20, 
ACR50 and ACR70 response rates were significantly 
higher in infliximab compared with placebo recipients. The 
infliximab groups showed less radiographic progression 
than the placebo group. Finally, physical function (assessed 
by HAQ) improved more in infliximab groups than in the 
placebo group.
The third large study investigating the efficacy of 
infliximab in early RA was the BeST study (BeST is a Dutch 
acronym for “Behandel Strategieën”, treatment strategies).27 
The aim of BeST was to define the best treatment strategy 
for preventing the outcome of functional ability (as 
measured by Health Assessement Questionnaire, HAQ) 
and the radiographic progression in early RA patients. The 
BeST study combined early introduction of treatment with 
intensive therapy adjustments based on programmed disease 
monitoring (every 3 months) using a disease activity score 
based on 44 joints until low disease activity of RA (defined 
as a score 2.4). The BeST study compared four treatment 
strategies: sequential monotherapy (group 1), step-up com-
bination therapy (group 2), step-down strategy (group 3 and 
4) using tapered high dose prednisone, MTX or sulfazalasine 
(group 3), or infliximab with MTX (group 4). After 2 years 
of treatment, there was no difference in clinical symptoms 
between the four groups: the goal of Disease Activity Score 
(DAS) 44 low activity was reached by more than 75% of 
RA patients in each group, and a clinical remission was 
observed in 40% to 45% of RA patients.28 Nevertheless, in 
this population of early RA, the radiographic progression 
was less important in groups 3 and group 4 than in groups 1 
and 2. After 1 year, the median increase in the total Sharp 
score was 2 in group 1, 2.5 in group 2, 1 in group 3 and 
0.5 in group 4.27 After 2 years, 40% of patients in group 1, 
34% in group 2, 20% in group 3 and 18 % in group 4 had a Biologics: Targets & Therapy 2009:3 186
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damage radiographic progression greater than the smallest 
detectable difference.28 Of importance, more patients in 
groups 3 and 4 were able to taper and discontinue drugs 
of the initial combination therapy, because of a continuous 
low disease activity.29 In group 4, 67% of patients having 
a DAS  2.4 for over 6 month were able to discontinue 
initial infliximab. The follow up of these patients for 5 years 
suggested that the remission reached in patients treated early 
with infliximab could be more sustainable than remission 
obtained in patients treated with infliximab as a second or 
more line of treatment.30 The importance of early interven-
tion with infliximab in RA has also been highlighted in a 
Japanese study31 which suggests that infliximab treatment 
in early RA could be advantageous for both achieving 
clinical remission and for discontinuing infliximab after 
clinical remission.
Infliximab and structural damage
The ATTRACT and ASPIRE studies provide evidence 
that infliximab is capable of slowing down structural joint 
damage.24–26,32 These two studies also provide an opportunity 
to examine the relationship between inflammation and bone 
damage. In both studies, infliximab in addition to MTX has 
shown a remarkable efficacy in preventing radiographic 
progression, with a similar efficacy in both clinical 
responders and non-responders.32–34 On the other hand, in 
ASPIRE, MTX was also able to slow down radiographic 
progression, but only in patients who were in remission after 
3 months of treatment.34 In clinical non-responders, MTX 
used in monotherapy led to a markedly worse radiographic 
progression. These observations are consistent with a direct 
role of TNF in inflammatory joint destruction. They also 
support the concept that efficacies against clinical disease 
and against joint damage could be dissociated from each 
other in patients treated by TNF antagonists.8
The efficacy of infliximab in preventing joint destruction 
has also been observed with imaging techniques more 
sensitive than radiography.35–37 Evolution of RA synovitis 
was evaluated by magnetic resonance imaging (MRI) in 
RA patients treated with MTX, with symptom duration less 
than 12 months.35,36 After 1 year, the combination of MTX 
plus infliximab was superior to MTX monotherapy for 
reducing MRI-detected signs of synovitis, bone edema and 
erosion score. Another study used ultra-sonography in 24 
RA patients, with disease duration 3 years.37 Sonography 
enabled the evaluation of synovial thickness. This study also 
showed a significant improvement in the infliximab group 
compared with placebo.
Infliximab dose adjustement  
in daily practice
Infliximab is the only licensed TNF blockade that is 
administered by infusion, with a dosage adapted to patient 
weight. The recommended posology for infliximab in RA 
is 3 mg/kg given as an intravenous infusion followed by 
additional 3 mg/kg infusion doses at 2 and 6 weeks after the 
first infusion, then every 8 weeks thereafter. Methotrexate 
should be given in combination with infliximab. One feature 
of infliximab compared to other anti-TNF blockades is that 
the dosage can be adjusted in case of insufficient response 
or secondary response failure. The dose of infliximab can 
be increased up to 10 mg/kg or the treatment interval can 
be decreased to every 4 weeks.24 The efficacy of dose or 
dose frequency adjustments of the infliximab therapies has 
been reported in literature.38–48 In several studies, including a 
meta-analysis of 8510 RA patients treated by infliximab, 50% 
to 60% of patients required dose escalation.38,42,43 The average 
dose is 5 mg/kg, increasing most rapidly until the end of the 
first year.38 The elapsed time to dose escalations ranged from 
128 to 254 days. The dose increase was more frequent than 
the shortening of interval between infusions42 but the reason 
for this was not clearly explained. It has been hypothesized 
that patients who flare during the 8-weekly interval eliminate 
infliximab more rapidly than patients with a constant 
response pattern and need a interval shorter than 8 weeks.47 
On the other hand, higher infliximab doses appeared to be 
more effective than standard 3 mg/kg dose for patients with 
severe disease activity.48 Nevertheless, efficacy of the dose 
adjustments was observed, with a range increase of ACR20 
response from 27% to 36% and an improvement in DAS. The 
available data support partial effectiveness of the infliximab 
dose adjustement in case of secondary response failure.
Immunogenicity of infliximab
Infliximab being a chimeric molecule, human anti-chimeric 
antibodies (HACA), also called antibodies to infliximab (ATI) 
may appear.49 Trough level assessments of anti- TNFα drugs 
and measurements of antibodies against these biologicals 
are among the parameters that best predict the response of 
individual RA patients.50 Several studies have shown that 
secondary response failure was associated with low trough 
levels of anti-TNFα biologicals and the development of 
antibodies against these drugs.49–51 Moreover, AT correlate 
with trough levels of circulating infliximab and subsequently 
with response failure.50
ATI has been demonstrated in 7% to 61% of the patients 
with psoriasis, Crohn’s disease and RA.52,53 These widely Biologics: Targets & Therapy 2009:3 187
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diverging incidences of ATI development can be attributed 
to the varying risk factors for their development and the 
association with other drugs in the treatment protocols. The 
schedule of infliximab administration has been reported to 
influence of ATI development. Loading the infliximab therapy 
with three infusions at weeks 0, 2 and 6 is probably less 
immunogenic that only one starting dose. Also, maintenance 
treatment (an infusion every 8 weeks) is generally advised 
instead of on demand treatment to prevent ATI formation.53 
The dosage of infliximab (3 or 5 mg/kg) does not seem to 
influence the formation of ATI or the development of infusion 
reactions. However, the low dose of infliximab (1 mg/kg) 
used in the first trial was associated with an increased of 
ATI formation.21 Co-medication with immuno-suppressants 
is thought to reduce the immunogenicity of infliximab.49,52 
ATI formation was significantly lower in patients co-treated 
with MTX.54,55 Nothing is known about ATI formation in the 
combination of infliximab with other DMARDs.
Combination of infliximab 
and DMARDs
Infliximab has been approved for use only in combination 
with MTX. This combination reduces immunogenicity and 
improves efficacy of the TNF blocker. However, combination 
of infliximab with DMARDs other that MTX has also been 
reported.56–62 The most studied combination is infliximab 
in association with leflunomide.56–61 In the first published 
studies, with few patients, a high frequency of cutaneous 
reactions, skin rash and vasculitis was observed, even though 
the efficacy of such a combination was also reported.56,57 
Nevertheless, these side effects were not reported in others 
studies. In open-label or retrospective studies,58,59,61,62 good 
efficacy and no increase in the side effects were observed with 
such combination. More recently, in a longitudinal observa-
tional study of a population-based cohort of RA patients, it 
has been demonstrated that the combination infliximab plus 
leflunomide present the same efficacy and tolerance profile as 
the combination MTX plus infliximab.61 The combination of 
infliximab with other DMARDs has also been studied, with 
the same profile of efficacy and tolerability as the infliximab 
and MTX combination.59–61 However, the effects of such 
combinations on ATI formation are not known.
Safety of infliximab in RA patients
The three TNFα blockers, including infliximab, have 
proven to be well tolerated in their clinical development 
programs. Additional information about the safety profiles 
of infliximab was provided by a large placebo-controlled 
trial, the START study (Safety Trial for Rheumatoid 
Arthritis with Remicade infliximab Therapy), whose aim 
was to assess the safety of infliximab treatment,63 and by 
postmarketing surveillance.
Infusions reactions
During and after intravenous administration of infliximab, 
infusions reactions can occur, as with other foreign 
protein-derived treatments. Infusion reactions during infusion or 
in the first 24 hours afterwards are defined as acute reactions.53 
The majority occur during or in the first 2 hours after infusion, 
and include headaches flushing, fever, chills and, more rarely, 
urticaria, dyspnea or hypotension. Delayed reactions are those 
occurring between 24 hours and 14 days after infusion, most 
after 5 to 7 days. Mild to moderate infusion reactions may 
occur in up to 20% of patients and many can be treated by 
slowing the rate of infusion.63 More severe infusion reactions 
occur in 2% to 3% of patients and may lead to discontinuation 
of therapy.64 The presence of ATI increases the incidence of 
infusion reactions.49 In RA, treatment with infliximab without 
MTX is an independent risk factor for development of infusion 
reactions: 16% of patients with MTX developed infusion reac-
tions compared to 40% without MTX.53
Infections
Infections are the main adverse event reported with the use 
of TNF blockers, with a spectrum of pathogens ranging from 
common bacteria to more opportunistic organisms such as 
Mycobacterium tuberculosis (tuberculosis).5,64 The risk of 
infections has been analyzed in the large START study,63 
which included 1084 RA patients, randomized into 3 groups: 
MTX with placebo, or with infliximab, 3 mg/kg and 10 mg/
kg. At week 22, taking account of corticosteroid treatment, 
the relative risk (RR) for developing a serious infection was 
2.0 (95% CI 0.8–5) in combined group of patients receiving 
infliximab. In the 3 mg/kg group, the RR of serious infec-
tions was 1 (95% CI 0.3–3.1), increasing up to 3.1 (95% CI 
1.2–7.9, p = 0.013) in the 10 mg/kg group. The most common 
infectious adverse event was respiratory tract infections.65,66 
In a meta-analysis published in 2006 by Bongartz et al67 the 
pooled odd ratios for serious infections based on 3493 and 
1512 patients who had received anti-TNFα antibody or pla-
cebo, respectively, was 2.0 (95% CI 1.3–3.1) for anti-TNF 
antibody therapies. This risk of infections is enhanced by 
the presence of pre-existing infections, long-standing RA, 
extra-articular manifestations, comorbidities and prednisone 
therapy.64 The risk increases with high dose therapy of 
infliximab.63 However, the frequency of infections is also Biologics: Targets & Therapy 2009:3 188
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increased in RA patients without biological treatment, 
compared to healthy controls.68
Tuberculosis (TB) is the most frequent opportunistic 
infection that has been reported with TNFα antagonists. 
During the first years following the launch of infliximab, 
postmarketing surveillance in Crohn’s and rheumatoid 
diseases reported 70 cases of TB with some clinical 
characteristics: the median interval between the start of 
infliximab and the onset of TB was short, about 12 weeks; 
the median number of infusions until diagnosis of TB 
was 3; 40% of the patients had extra-pulmonary disease, 
17 with a disseminated disease.69 According to these data, 
it was suggested that infliximab was associated with the 
development of TB. Most of these TB infections occurred in 
the first 6 to 8 months of use, although a more variable latency 
period was observed if etanercept was used compared with 
infliximab. This chronology suggests reactivation of latent 
TB with the use of anti-TNF antibodies.64,69–71 Now there 
is an emerging consensus for a 5- to 10-fold increased risk 
of TB reactivation by anti-TNF antibodies but no or only a 
slightly increased risk of reactivation is associated with the 
use of the anti-TNF soluble receptor etanercept.64,71 TNFα 
plays a role in host defence against M. tuberculosis, notably 
in stimulating the granulomatous inflammation necessary for 
the containment and sequestration of these pathogens.70–73 
Anti-TNFα antibodies are able to disrupt the integrity of 
granulomas and exacerbate TB infections. Recommendations 
for the diagnosis and treatment of latent and active TB in 
patients treated with anti-TNFα agents have emerged.74–77 
These guideless include the screening methods to be used 
in these patients and the prophylactic treatments. Adherence 
to the recommendations is able to reduce the reactivation of 
latent TB.78 Some opportunistic infections have also been 
reported with the use of infliximab, including histoplasmosis, 
listeriosis, pulmonary, aspergillosis and pneumocystis carinii 
pneumonia.5,64
Malignancies and lymphomas
The second major concern has been malignancies. Spontaneous 
postmarketing surveillance identified a number of cases 
of lymphoma under anti-TNFα antagonists. The FDA’s 
postmarketing adverse event surveillance system collected 
and published 26 cases of lymphoma, 18 patients on etan-
ercept and 8 on infliximab.79 The estimated lymphoma rate 
among patients was evaluated to be 6.6 cases in 100 000 for 
those being treated with infliximab. The majority of cases were 
Non-hodgkin’s lymphomas and the median interval between 
the initiation of anti-TNFα antagonists and the development 
of lymphoma was short, only 8 weeks.79 This rapidity of lym-
phoma development raises the possibility that the anti-TNF 
agents might reveal a latent lympho-proliferative disorder. 
Others reports have also suggested an increased frequency of 
lymphomas in patients treated with anti-TNF antibodies: In a 
meta-analysis of malignancies under anti-TNFα antibodies, 
the pooled OR was estimated to be 3.3 (95% CI 1.2–9.1) and 
the risk was higher in patients treated with higher doses than 
in those receiving lower doses of monoclonal antibodies.67 
However, the relationship between anti-TNF blockers and the 
appearance of lymphoma is not clear. The risk of lymphoma 
is increased in RA patients without anti-TNF blockers, with 
and without MTX.80,81 The standardized incidence ratio (SIR) 
for lymphoma was calculated from the national databank for 
rheumatic disease in the US. In patients with RA, the overall 
SIR for lymphoma was 1.9 (95% CI 1.3–2.7), whereas SIR 
for biological treatments was 2.9 (95% CI 1.4–4.5). The SIR 
was 2.6 (95% CI 1.4–4.5) for the use of infliximab, 1.7 for the 
use of MTX and 1.0 for RA patients not receiving MTX or 
biologicals.80 There is also strong evidence that the increase 
risk of lymphoma in RA patients is related to disease activity 
itself, independently of treatments.82 However, eight cases 
of a rare cancer, hepatosplenic T-cell lymphoma (HSTL), 
were recently described in young patients with inflammatory 
bowel disease treated by infliximab and concomitant 
immunosuppression.83 Treatment with infliximab necessitates 
a close monitoring of the patients.
For solid cancers, no overall increased risk has been 
reported in registry studies. However, an increase of skin 
cancers has been observed with biologics67,81 and the skin 
should be carefully watched.
Taken together, the data do not support an increased risk 
for solid cancer, except for the skin, but a slightly increased 
risk for lymphoma for patients receiving anti-TNF agents.
Demyelinating diseases
Multiple sclerosis (MS), optic neutitis and others forms of 
demyelinating neurological dysfunction have been reported 
with use of anti-TNF blockers.64,84,85 Observed adverse 
events include new onset and exacerbation worsening of 
pre-existing demyelinating diseases. Other than a prior history 
of demyelinization disease, no predictive factor has been 
identified. Partial or complete resolution was obtained with 
cessation of anti-TNFα therapy. The mechanisms that could 
explain such neurological events remain unclear. Therefore, 
it is strongly recommended that the anti-TNFα treatments 
should be stopped when neurological events occur, and strictly 
avoided in patients with pre-existing demyelination diseases. Biologics: Targets & Therapy 2009:3 189
Infliximab for rheumatoid arthritis Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Peripheral neuropathy with varying degrees of motor and sen-
sory involvement were also described in RA patients receiving 
infliximab.85
Drug-induced auto-immunity
Increased frequency of auto-antibodies has been reported 
after treatment with anti-TNF, the frequency being greater 
with infliximab.86 In the ATTRACT study, 23% of patients 
developed antinuclear antibodies (ANA) and 16% became 
positive for anti double-stranded DNA (anti-dsDNA) anti-
bodies.22 In the ASPIRE study, 39.6% and 34.3% of patients 
receiving infliximab 3 and 6 mg/kg, respectively, became 
positive for ANAs.26 However, in clinical practice, the 
development of these antibodies is not associated with the 
occurrence of systemic auto-immune diseases.87
Other side effects
Anti-TNFα therapies have been associated with congestive 
heart failure and these biological treatments are contra-
indicated in patients with a history of NYHA III or IV 
heart failure.74,88 An increase in the liver function test, and 
pancytopenia, has also been associated with anti-TNFα 
use.64 Congenital anomalies have recently been observed in 
children born to mothers taking TNF antagonist.89 Anti-TNF 
antagonists must be stopped before pregnancy.
Conclusion
After more than 10 years of commercialization, infliximab is 
a leading treatment of RA, with a good efficacy and high tol-
erance. Infliximab is the only licensed TNF antagonist given 
by infusion, enabling dose adjustment and, for some patients, 
some rescue of response failure. The favorable results with 
infliximab use opened the way for the development of new 
anti-TNF biodrugs and for the use of new biological agents 
in RA treatment. Today, patients with secondary response 
failure to one anti-TNFα drug could benefit from switching 
to another anti-TNFα drug or another biological.90 However, 
the use of infliximab, like the other anti-TNFs, is associated 
with an increase in side effects, especially infections, and 
close monitoring of the treated patients is needed.
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